With the potential to become the first to win US Food and Drug Administration approval for a T-cell therapy in a solid tumor indication, Adaptimmune Therapeutics plc is already thinking about how to commercialize the product, the T-cell receptor (TCR) therapy afamitresgene autoleucel. But while the initial focus will be on the tiny market for synovial sarcoma, the firm has its eye on potentially much larger markets.
The Philadelphia- and Oxfordshire, UK-based company said 19 May that it would report initial data from the pivotal Phase II...
